PDCD1 and non-small cell lung carcinoma: CheckMate‐063 was a phase II clinical trial testing nivolumab, a humanized IgG4 anti‐PD‐1 monoclonal antibody, in patients with stage IIIB/IV squamous NSCLC who had received at least two previous treatments, one of which was a platinum‐based doublet 48.